Incyte reports 71% response rate for INCA33890 combination in Phase 1 colorectal cancer trial

Bitget2026/10/26 13:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Incyte presented early-stage results for cancer treatments INCB161734 and INCA33890 at the ESMO Congress 2026.
INCB161734 combinations showed durable responses in pancreatic cancer and antitumor activity in previously treated colorectal cancer, with manageable safety.
INCA33890 with standard therapies showed preliminary activity across microsatellite-stable colorectal cancer patient groups, with manageable safety.
Phase 3 pancreatic cancer results for INCB161734 are expected in 2028; its colorectal cancer trial should begin in the first half of 2027.
The ongoing Phase 3 trial of INCA33890 with chemotherapy and bevacizumab in first-line microsatellite-stable colorectal cancer expects results in 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261026987057) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Incyte reports 71% response rate for INCA33890 combination in Phase 1 colorectal cancer trial

You may also like

Crypto prices